The National Institute on Aging and Alzheimer's Association (NIA‐AA) have proposed classifying Alzheimer's disease (AD) based on biomarkers of amyloid pathology (A), tau pathology (T), and neurodegeneration (N).1 This evidence concerns the gene MAPT and Alzheimer disease.